Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome
International Journal of Molecular Sciences · 21.08.2026 · 27 (16) · 7473
DOI: 10.3390/ijms27167473 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.08.2026. Verfasst von Daniela Koleva-Tyutyundzhieva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Insulin Resistance, Endothelium, Vascular. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine–metabolic disorder frequently associated with insulin resistance (IR) and increased cardiovascular risk. Soluble CD40 ligand (sCD40L) and soluble E-selectin (sE-selectin) are circulating biomarkers reflecting immune activation and endothelial dysfunction, respectively. However, their differential associations with IR in PCOS, particularly in the context of central obesity, remain incompletely understood. This cross-sectional study included 80 women with PCOS stratified according to waist-to-height ratio (WHtR > 0.50 vs. ≤0.50). Clinical, metabolic, hormonal, inflammatory, and endothelial parameters were evaluated. Correlation and multivariable regression analyses were performed to identify independent determinants of circulating sCD40L and sE-selectin. Women with central obesity exhibited significantly higher fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), triglycerides, non-high-density lipoprotein (non-HDL) cholesterol, systolic blood pressure (SBP), and sE-selectin concentrations, together with lower HDL cholesterol. No significant differences were observed in tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), or sCD40L. In adjusted regression models, fasting glucose independently predicted sCD40L (β = −0.27, 95% confidence interval (CI): −0.50 to −0.04, p = 0.020), whereas fasting insulin emerged as the strongest determinant of sE-selectin (β = 0.41, 95% CI: 0.17 to 0.65, p < 0.001). These findings suggest distinct associations of immune and endothelial biomarkers with IR in PCOS. Assessment of sCD40L and sE-selectin may provide complementary information for early cardiometabolic risk stratification in affected women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Diagnostic Imaging, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
- Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Clinical Laboratory, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Zitieren
APA
Koleva-Tyutyundzhieva, D., Ilieva-Gerova, M., Nyagolova, P., Konsulova, P., Babadzhanova, E., Georgiev, A., Kansara, D., Deneva, T., & Orbetzova, M. (2026). Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 27(16), 7473. https://doi.org/10.3390/ijms27167473
Vancouver
Koleva-Tyutyundzhieva D, Ilieva-Gerova M, Nyagolova P, Konsulova P, Babadzhanova E, Georgiev A, et al. Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome. International Journal of Molecular Sciences. 2026;27(16):7473. doi:10.3390/ijms27167473
BibTeX
@article{KolevaTyutyundzhieva2026,
author = {Koleva-Tyutyundzhieva, Daniela and Ilieva-Gerova, Maria and Nyagolova, Presiyana and Konsulova, Petya and Babadzhanova, Ekaterina and Georgiev, Aleksandar and Kansara, Devarshi and Deneva, Tanya and Orbetzova, Maria},
title = {Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7473},
doi = {10.3390/ijms27167473}
}
EUVIMED